Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci

NCT07013552 is registered in ClinicalTrials.gov with Medical University of Silesia as lead sponsor.

NCT NCT07013552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci
Lead sponsor
Medical University of Silesia
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
October 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotic resistant strain, antibiotic therapy, cardiac implantable electronic device infections, gram positive bacterial infection, healthcare associated infections, infective endocarditis, multidrug-resistant bacteria screening